معرفی
Klaus Okkenhaug is Professor of Immunology at the University of Cambridge's Department of Pathology. His work focuses on the roles of phosphoinositide 3-kinases (PI3K) in immunity, infection, and cancer, with major contributions to understanding how these enzymes regulate lymphocyte activation and tumor-immune interactions.
- BSc in Biochemistry from University of Victoria, Canada
- PhD in Immunology from University of Toronto
- Postdoctoral work at Ludwig Institute for Cancer Research, London
- Group Leader at Babraham Institute (2003–2017)
His research has led to the development of clinically used PI3K inhibitors. Current interests include Treg function, metastasis suppression, and crosstalk between immune and metabolic pathways. Recent studies highlight his work on:
- Nature (2025): Aspirin's role in TXA2-mediated immune activation against metastasis
- Science (2025): Computational design of synthetic TCRs for cancer therapy
- Frontiers in Immunology (2025): VPS34's role in regulatory T cell suppression
Klaus actively advises pharmaceutical companies and collaborates across disciplines. He serves as:
- Head of the Division of Immunology
- Postgraduate Tutor at Magdalene College
- Editorial board member for immunology journals
۰مقاله منتشرشده
